The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Actym Therapeutics; Aduro Biotech; Alphamab; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; Compugen; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Mavu Pharmaceutical; Merck; Newlink Genetics; Novartis; Reflexion Medical; Spring Bank; Syndax; Tempest Therapeutics; TTC Oncology; Vividion Therapeutics; WntRx Pharmaceuticals
Research Funding - Abbvie (Inst); Array BioPharma; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Checkmate Pharmaceuticals; Compugen (Inst); Corvus Pharmaceuticals (Inst); Delcath Systems (Inst); Evelo Therapeutics; Five Prime Therapeutics (Inst); FLX Bio; Genentech/Roche (Inst); Immunocore (Inst); Incyte (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Palleon Pharmaceuticals; Pharmacyclics (Inst); Tesaro (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Merck; Novartis; Reflexion Medical
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Incyte; MedImmune; Merck Serono; Merck Sharp & Dohme; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma; Syndax; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Alexander M. M. Eggermont
Honoraria - Actelion; Agenus; Bristol-Myers Squibb; GlaxoSmithKline; HalioDx; Incyte; ISA Pharmaceuticals; MedImmune; MSD; Nektar; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Actelion; Bristol-Myers Squibb; GlaxoSmithKline; HalioDX; Incyte; ISA Pharmaceuticals; MedImmune; MSD; Nektar; Novartis; Pfizer; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Jean-Jacques Grob
No Relationships to Disclose
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; Merck Serono; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche
 
John M. Kirkwood
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Immunocore; Novartis; Roche
Research Funding - Immunocore (Inst); Merck (Inst); Prometheus (Inst)
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Incyte; Merck; Novartis; Roche
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; Pierre Fabre; Roche/Genentech
 
Peter Mohr
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche/Genentech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Research Funding - Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
 
Caroline Robert
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Serono; Novartis; Pierre Fabre; Roche
 
Jeffrey E. Gershenwald
Consulting or Advisory Role - Castle Biosciences; Merck
Patents, Royalties, Other Intellectual Property - mercator therapeutics
 
Andrew Stewart Poklepovic
Consulting or Advisory Role - Castle Biosciences; Merck; Novartis
Speakers' Bureau - Bristol-Myers Squibb
 
Merrick I. Ross
Honoraria - Amgen; Merck
Consulting or Advisory Role - Amgen; Merck
Speakers' Bureau - Amgen
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Amgen; Merck
 
Richard A. Scolyer
No Relationships to Disclose
 
Charles Yoon
Consulting or Advisory Role - Merck
 
James R. Anderson
Employment - Merck
 
Sama Ahsan
Employment - Merck
 
Nageatte Ibrahim
Employment - Merck
Stock and Other Ownership Interests - GlaxoSmithKline; Merck
 
Vernon K. Sondak
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Castle Biosciences; EMD Serono; Genentech/Roche; Illumina; Merck/Schering Plough; Novartis; OncoSec; Pfizer; Polynoma; Sun Pharma